UnitedHealth's Optum Rx to change its payment models
UnitedHealth Group's pharmacy benefit manager Optum Rx is making changes to its payment models. Optum Rx will tweak its payment models in full force by January 2028 to more closely reflect the high...
View ArticleElevation Oncology stops work on ADC, lays off workers; AstraZeneca’s CEPI...
Plus, news about Century Therapeutics, Akebia Therapeutics, Eyenovia, Betaliq, Alvotech, Genenta Science, Aadi Bioscience, and Exicure: Elevation Oncology drops ADC, lays off 70%: The Boston-based drug...
View ArticleMerck to lay off 163 workers in Pennsylvania; Delpharm gets $60M from...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Merck plans to lay off 163 staffers as it closes its facility in...
View ArticleVisen Pharmaceuticals prices $86M Hong Kong IPO
Visen Pharmaceuticals, a biotech developing much of Ascendis Pharma’s endocrine-related disease pipeline for the China market, will go public on the Hong Kong Stock Exchange on Friday. The company...
View ArticleGoogle is building AI healthcare helpers
It feels like people have gotten a lot more comfortable with using AI day to day. Every spring, I go to Google’s office in New York to see how the tech giant’s applying its technology ...
View ArticleSV Health Investors nabs $250M to fund dementia-focused biotechs
SV Health Investors has added $250 million to its hunt for new therapeutics for dementia, Alzheimer's and other neurodegenerative diseases. The London-based life sciences investor secured that amount...
View ArticleCalley Means joins White House as a special government employee
A close ally of HHS Secretary Robert F. Kennedy Jr. is joining the administration as a special government employee, according to a source familiar with the decision. Calley Means, an entrepreneur and...
View ArticleNovo Nordisk lays out new structure for early R&D unit
Novo Nordisk is reorganizing its research and early development unit in an effort to “future-proof the organization” and “significantly increase” the number of projects it brings into clinical trials,...
View ArticleMany rare disease drugs rely on just one trial for approval, FDA authors find
New research published by FDA authors found that 67% of non-oncologic rare disease marketing applications approved between 2020 and 2023 used only one clinical trial plus confirmatory evidence to...
View ArticleAkero exec calls MASH accelerated approval guidance 'bizarre'
NEW YORK — Akero Therapeutics may not have adequate data for accelerated approval of its MASH drug, despite showing it may reverse cirrhosis in patients with severe liver disease. The problem, chief...
View ArticleACIP meeting, delayed earlier this year, is rescheduled
A meeting of CDC vaccine advisors that’s been in limbo for almost a month is slated to take place around the middle of April, two sources familiar with the planning told Endpoints News. A spokesperson ...
View ArticleBridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion's...
→ Brian Stephenson has stepped down after more than five years as CFO of BridgeBio, and president Tom Trimarchi will take over. Trimarchi was promoted to president and COO last July. “It has been an ...
View ArticleExclusive: VantAI builds AI model Neo-1 for molecular glues
A Roivant Sciences spinout says it has made the first AI model, to its knowledge, that simultaneously predicts biomolecule structures while generating new molecules. The diffusion-based model, called...
View ArticleJohnson & Johnson earmarks $55B to boost US capacity
Johnson & Johnson is planning to invest $55 billion to build up its US footprint over the next four years, becoming the latest pharma company to pour billions into the country. As a part of ...
View ArticleAstraZeneca broadens presence in China, promising $8B+ to Harbour and Syneron
AstraZeneca is further investing in China, opening an R&D center in Beijing and inking a pair of majorly backloaded R&D deals with Chinese drug developers. The Harbour BioMed and Syneron Bio...
View ArticleAstraZeneca puts $2.5B toward first vaccine factory and second R&D site in China
AstraZeneca is again boosting its manufacturing footprint in China, this time making a $2.5 billion investment to build its first vaccine plant and second R&D facility in the country. As a part of...
View ArticleGenfit's up to €185M royalty deal; J&J’s Tremfya gets a Crohn's approval
Plus, news about Akeso, Pulmatrix, Autolus, MacroGenics and BlissBio: Genfit completes up to €185M royalty deal: Per the agreement with HealthCare Royalty, the company gets €130 million ($141 million)...
View ArticleFDA approves Novartis’ Fabhalta in C3 glomerulopathy
Novartis’ Fabhalta notched another FDA approval, this time in adults with an ultra-rare kidney disease called C3 glomerulopathy. Fabhalta is the first drug approved specifically to treat C3...
View ArticleThe buildup to Chimerix's $935M cash exit to Jazz
Chimerix began attracting deal interest in its experimental brain tumor treatment about 18 months before it signed a $935 million cash exit to Jazz Pharmaceuticals earlier this month, according to a...
View Article